Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV002284170 | SCV002573721 | likely pathogenic | not provided | 2022-08-25 | criteria provided, single submitter | clinical testing | PS4_moderate, PM2, PP1, PP5 |
Labcorp Genetics |
RCV002284170 | SCV004292937 | uncertain significance | not provided | 2023-10-23 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 261 of the SPTA1 protein (p.Ser261Pro). This variant is present in population databases (rs121918636, gnomAD 0.007%). This missense change has been observed in individual(s) with SPTA1-related disorders (PMID: 2794061, 29729090). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is also known as p.Ser255Pro. ClinVar contains an entry for this variant (Variation ID: 12848). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SPTA1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
OMIM | RCV000013701 | SCV000033948 | pathogenic | Elliptocytosis 2 | 1989-10-01 | no assertion criteria provided | literature only |